• Midatech Pharma PLC (NASDAQ: MTP) has announced a breakthrough in vitro data utilizing Q-Sphera technology and progress across multiple other programs.

• The technology showed potential to formulate proteins into long-acting injectable products.

• Q-Sphera can encapsulate drugs in polymer-based bioresorbable microspheres, which may be injected to form depots in the body that release drugs over predictable, sustained periods from one week to several months.

• Pipeline Update:

  • Monoclonal antibody (mAb) formulation: The Company is working on an exemplar mAb and has demonstrated encapsulation of the mAb, preservation of functional integrity, and antigen-binding in vitro.

  • MTX214 and MTX216: The Company has manufactured and delivered proof of concept formulations to the collaboration partner. Dosing for in vivo studies will start in the next few weeks.

  • MTD211: MTP has developed a long-acting formulation of brexpiprazole.

  • In in vivo studies, MTD211 was well tolerated and demonstrated that a single dose could deliver therapeutic blood levels of brexpiprazole over three months.

  • Marketed under the brand name Rexulti, brexpiprazole is indicated to treat schizophrenia and adjunctive treatment of major depressive disorder and is available as an immediate release oral tablet.

  • MTX110: Formulated panobinostat administered through convection-enhanced delivery, is in clinical development for intractable brain cancers including Diffuse Intrinsic Pontine Glioma (DIPG) and Glioblastoma Multiforme (GBM).

  • Phase 2 study in DIPG will start later this year.

  • Midatech Pharma's strategy is to develop each program to proof-of-concept before seeking licensing partners for later-stage development and commercialization.

• The Company will be hosting a webinar at 9.00 am EST today.

• Price Action: MTP shares are up 74% at $3.55 during the premarket trading session on the last check Thursday.

See more from Benzinga

• Click here for options trades from Benzinga

• Satsuma Stock Is Trading Higher As STS101 Shows Favorable Pharmacokinetic Profile, Tolerability In Early-Stage Study

• PureTech Adds Inflammatory Disease Candidates To Pipeline With Alivio Buyout

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.